Replimune Group Inc (REPL) Stock Price, Quote & News

Company Profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express a...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 222 9600

Website: www.replimune.com

Address:

500 Unicorn Park Drive, Suite 303, Woburn, United States

History101 Jul. 3 at 10:04 PM

$REPL stock price action week of Mon June 29, 2026

0 · Reply

Benalish Jul. 3 at 1:07 AM

$OMER $QURE $REPL

1 · Reply

ChartSherpa Jul. 2 at 2:52 PM

$REPL the $IOVA pumpers tried their best to mislead you. Sorry to whoever listened to them instead of me, and tried to short this. Sometimes it’s difficult for non-technical people to understand and value a company, which can definitely happen sometimes. When it comes to biotech/pharma, listen to actual scientists. Also, biotechs always do well during this presidential seasonality. The stupidity is tragic, but unfortunately the idiots will never listen to reason or shut up

5 · Reply

Neolander Jul. 2 at 4:03 AM

$NTLA $REPL had a trial rejected by FDA and resubmit. $ABVX Abivax seems to causes cancer (later proved false ). Their stocks went back to their previous price within a few weeks. While NTLA are still in deep discount. NTLA Got a platform, not just a product! There will be a streamline of products including CART. Check their patents !!

0 · Reply

mimiwor Jul. 1 at 6:21 PM

$REPL They have been shorted this thing all day long.imao and just realized we are not even $1.X billion cap yet...

0 · Reply

Merlintrader Jul. 1 at 5:53 PM

$REPL Replimune Group Stock Hub: RP1, the FDA Resubmission and the Last Chance for an Oncolytic Melanoma Story https://www.merlintrader.com/replimune-group-stock-hub/

0 · Reply

jtsxlr Jul. 1 at 3:40 PM

$ZENA , $REPL , $VRRM I do believe retail lost interest in these , not me, not yet

0 · Reply

beachsidefreddy Jul. 1 at 12:10 PM

$REPL "DOWN GOES FRAZIER .....DOWN GOES FRAZIER"!!!!!!!

0 · Reply

Wagner2000 Jul. 1 at 1:07 AM

$VTGN not pumping it because I bought dip today,however will give a good example $REPL when it collapsed to 1.70 back in April. Now it"s 11 bucks. Who remembers that?

3 · Reply

jon10Trllion Jun. 30 at 6:14 PM

$REPL i reaaaaallyyy want to buy in but im scared. Damn. GL to those who are in

0 · Reply

Replimune price target raised to $9 from $6 at Wedbush

2026-06-30T11:00:23.000Z - 4 days ago

BMO double upgrades Replimune on higher chances of FDA approval

2026-06-29T15:15:09.000Z - 5 days ago

Replimune Group put volume heavy and directionally bearish

Jun 29, 2026, 8:00 AM EDT - 5 days ago

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

Jun 29, 2026, 8:00 AM EDT - 5 days ago

Replimune Group Earnings release: Q4 2026

Jun 29, 2026, 8:00 AM EDT - 5 days ago

Replimune Group Annual report: Q4 2026

2026-06-26T15:40:10.000Z - 8 days ago

JPMorgan upgrades Replimune on RP1 application resubmission

2026-06-26T15:35:11.000Z - 8 days ago

Replimune upgraded to Overweight from Neutral at JPMorgan

2026-06-26T12:15:33.000Z - 8 days ago

Replimune announces FDA acceptance of RP1 biologics license application

Jun 26, 2026, 8:00 AM EDT - 8 days ago

Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma

2026-06-01T16:21:43.000Z - 4 weeks ago

Replimune Group trading resumes

2026-06-01T13:36:30.000Z - 4 weeks ago

Replimune Group trading halted, volatility trading pause

2026-06-01T13:07:02.000Z - 4 weeks ago

Replimune price target raised to $6 from $2 at Wedbush

2026-05-31T21:15:05.000Z - 4 weeks ago

Replimune presents final first-in-human data for RP2 alone, with nivolumab

2026-05-31T20:35:04.000Z - 4 weeks ago

Replimune presents 3-year overall survival data from IGNYTE trial

May 31, 2026, 8:00 AM EDT - 4 weeks ago

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 30, 2026, 8:00 AM EDT - 5 weeks ago

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 29, 2026, 9:53 PM EDT - 5 weeks ago

How Replimune's drug got a third chance after the White House intervened

2026-05-29T17:31:42.000Z - 5 weeks ago

Replimune upgraded to Neutral at JPMorgan with RP1 ‘back on the table’

2026-05-29T17:28:48.000Z - 5 weeks ago

Replimune upgraded to Neutral from Underweight at JPMorgan

2026-05-29T14:55:13.000Z - 5 weeks ago

Why Penny Stock Replimune (REPL) Nearly Doubled Today

BMY

May 29, 2026, 8:51 AM EDT - 5 weeks ago

Replimune to resubmit twice-rejected drug for approval after FDA shakeup

May 29, 2026, 8:07 AM EDT - 5 weeks ago

Replimune reaches agreement with US FDA to resubmit melanoma drug application

May 29, 2026, 8:00 AM EDT - 5 weeks ago

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

May 29, 2026, 7:30 AM EDT - 5 weeks ago

Replimune Gets Third Try at FDA Approval After Makary Departure

May 5, 2026, 10:58 AM EDT - 2 months ago

FDA Commissioner Makary defends agency's decision on Replimune's drug

Apr 22, 2026, 12:56 PM EDT - 2 months ago

US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

Apr 13, 2026, 11:46 AM EDT - 2 months ago

Replimune co-founder calls FDA rejection of melanoma drug ‘unfair'

Apr 10, 2026, 5:02 PM EDT - 3 months ago

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

Apr 10, 2026, 11:24 AM EDT - 3 months ago

US FDA declines to approve Replimune's drug for advanced skin cancer

Mar 9, 2026, 2:20 PM EDT - 4 months ago

Replimune Group Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 8:00 AM EST - 4 months ago

Replimune to Present at Two Upcoming Investor Conferences

Feb 3, 2026, 8:00 AM EST - 5 months ago

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Feb 3, 2026, 8:00 AM EST - 5 months ago

Replimune Group Quarterly report: Q3 2026

Feb 3, 2026, 8:00 AM EST - 5 months ago

Replimune Group Earnings release: Q3 2026

Jan 14, 2026, 4:30 PM EST - 6 months ago

Replimune Group Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 4:30 PM EST - 6 months ago

Replimune Group Slides: 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 8:00 AM EST - 7 months ago

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 7, 2025, 4:45 PM EST - 8 months ago

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Nov 6, 2025, 8:30 AM EST - 8 months ago

Replimune Group Earnings release: Q2 2026

Nov 6, 2025, 8:30 AM EST - 8 months ago

Replimune Group Quarterly report: Q2 2026

Nov 6, 2025, 8:00 AM EST - 8 months ago

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Nov 6, 2025, 7:00 AM EST - 8 months ago

Replimune Group Registration statement: Registration Filing

Oct 20, 2025, 7:00 AM EDT - 9 months ago

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Oct 19, 2025, 8:00 AM EDT - 9 months ago

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

Sep 18, 2025, 9:15 AM EDT - 10 months ago

Replimune Provides Update Following Type A Meeting with FDA

Sep 3, 2025, 11:30 AM EDT - 10 months ago

Replimune Group Transcript: AGM 2025

Sep 2, 2025, 8:00 AM EDT - 10 months ago

Replimune Announces Type A Meeting Scheduled with FDA

Aug 7, 2025, 8:00 AM EDT - 11 months ago

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Aug 7, 2025, 7:00 AM EDT - 11 months ago

Replimune Group Earnings release: Q1 2026

Aug 7, 2025, 7:00 AM EDT - 11 months ago

Replimune Group Quarterly report: Q1 2026

Jul 30, 2025, 8:36 AM EDT - 1 year ago

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

History101 Jul. 3 at 10:04 PM

$REPL stock price action week of Mon June 29, 2026

0 · Reply

Benalish Jul. 3 at 1:07 AM

$OMER $QURE $REPL

1 · Reply

ChartSherpa Jul. 2 at 2:52 PM

5 · Reply

Neolander Jul. 2 at 4:03 AM

0 · Reply

mimiwor Jul. 1 at 6:21 PM

$REPL They have been shorted this thing all day long.imao and just realized we are not even $1.X billion cap yet...

0 · Reply

Merlintrader Jul. 1 at 5:53 PM

$REPL Replimune Group Stock Hub: RP1, the FDA Resubmission and the Last Chance for an Oncolytic Melanoma Story https://www.merlintrader.com/replimune-group-stock-hub/

0 · Reply

jtsxlr Jul. 1 at 3:40 PM

$ZENA , $REPL , $VRRM I do believe retail lost interest in these , not me, not yet

0 · Reply

beachsidefreddy Jul. 1 at 12:10 PM

$REPL "DOWN GOES FRAZIER .....DOWN GOES FRAZIER"!!!!!!!

0 · Reply

Wagner2000 Jul. 1 at 1:07 AM

$VTGN not pumping it because I bought dip today,however will give a good example $REPL when it collapsed to 1.70 back in April. Now it"s 11 bucks. Who remembers that?

3 · Reply

jon10Trllion Jun. 30 at 6:14 PM

$REPL i reaaaaallyyy want to buy in but im scared. Damn. GL to those who are in

0 · Reply

Monkey7779192 Jun. 30 at 4:32 PM

$REPL Why would they aporove it this time?

2 · Reply

beachsidefreddy Jun. 30 at 2:03 PM

$REPL TOTAL SCAM $10 INCOMING

0 · Reply

csliumanila Jun. 30 at 12:35 PM

$REPL "BMO Capital Upgrades Replimune to Outperform From Underperform, Adjusts PT to $16 From $1" Published on 06/30/2026 MT Newswires

1 · Reply

notreload_ai Jun. 30 at 12:34 PM

BMO Capital upgrades $REPL to Outperform and raises PT to $16 after FDA accepts RP1 BLA with Class 1 review. PDUFA date set for August 2, 2026. https://notreload.xyz/xy/replimune-stock-gets-bmo-upgrade-to-outperform-as-fda-de-risks-rp1-approval/

0 · Reply

beachsidefreddy Jun. 30 at 12:18 PM

$REPL more BS from REPL CEO about earnings and cash ability to last. they will not get FDA and REPL is a $1 stock I am not joking. Their earnings sucked and were worse than expected. despite this idiocy BMO and others upgraded. idiots.

0 · Reply

theflynews Jun. 30 at 11:09 AM

BMO double upgrades Replimune on higher chances of FDA approval - $REPL - https://thefly.com/REPL

0 · Reply

luminouslumens Jun. 30 at 12:09 AM

$REPL $MBLY $HIVE $SLS

0 · Reply

beachsidefreddy Jun. 29 at 3:45 PM

$REPL $10 incoming!!

0 · Reply

Merlintrader Jun. 29 at 2:29 PM

$CAPR Three Nasdaq Biotech Stories That Matter Now: $UNCY’s OLC PDUFA, $CAPR’s FDA AdCom, and $REPL’s RP1 Resubmission https://www.merlintrader.com/biotech-radar-jun29/

0 · Reply

beachsidefreddy Jun. 29 at 2:15 PM

$REPL “DOWN GOES FRAZIER….DOWN GOES FRAZIER”!!!!

0 · Reply

d_risk Jun. 29 at 2:11 PM

$REPL - Replimune Group Inc - 10K - Updated Risk Factors REPL’s risk profile has intensified: RP1’s BLA for advanced melanoma has now twice been hit with FDA CRLs and faces an advisory committee before an August 2, 2026 action date, with no assurance of approval; leadership churn and policy shifts at FDA, possible foreign knock-on effects, potential RP1 restructuring fallout, and expanded global privacy/AI compliance risks further cloud the path to commercialization and funding. #Biotech #FDARegulatoryRisk #Oncology #DrugApprovalDelay #DataPrivacy 🟢 Added 🟠 Removed https://d-risk.ai/REPL/10-K/2026-06-29

0 · Reply

Macdaddy23 Jun. 29 at 1:45 PM

$REPL looks like they cut 55% of workforce after 2nd CRL

1 · Reply

Market Cap	972.08M
Revenue (ttm)	0.00
Net Income (ttm)	-247.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.23

Volume	2,844,700
Avg Vol	6,704,318
Day's Range	N/A - N/A
Shares Out	83.95M
Stochastic %K	65%
Beta	0.86
Analysts	Sell
Price Target	$9.17